Development of an Automatic Measurement Method for CD8 and PD-1 Positive T Cells Using Image Analysis Software.


Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Jan 2022
Historique:
received: 29 10 2021
revised: 19 11 2021
accepted: 22 11 2021
entrez: 31 12 2021
pubmed: 1 1 2022
medline: 13 1 2022
Statut: ppublish

Résumé

With the progress in cancer immunotherapy using immune checkpoint blockade (ICB) therapy, histological observations of tumor-infiltrating lymphocyte (TIL) status are needed to evaluate the antitumor effect of ICB using imaging analysis software. Formalin-fixed paraffin-embedded sections obtained from colorectal cancer and gastric cancer patients with more than 500 single nucleotide variants were stained with anti-CD8 and anti-PD-1 antibodies. Based on our own algorithm and imaging analysis software, an automatic TIL measurement method was established and compared to the manual counting methods. In the CD8 An imaging software-based automatic measurement could be a simple and useful tool for evaluating the therapeutic effect of cancer immunotherapies in terms of TIL status.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
With the progress in cancer immunotherapy using immune checkpoint blockade (ICB) therapy, histological observations of tumor-infiltrating lymphocyte (TIL) status are needed to evaluate the antitumor effect of ICB using imaging analysis software.
MATERIALS AND METHODS METHODS
Formalin-fixed paraffin-embedded sections obtained from colorectal cancer and gastric cancer patients with more than 500 single nucleotide variants were stained with anti-CD8 and anti-PD-1 antibodies. Based on our own algorithm and imaging analysis software, an automatic TIL measurement method was established and compared to the manual counting methods.
RESULTS RESULTS
In the CD8
CONCLUSION CONCLUSIONS
An imaging software-based automatic measurement could be a simple and useful tool for evaluating the therapeutic effect of cancer immunotherapies in terms of TIL status.

Identifiants

pubmed: 34969752
pii: 42/1/419
doi: 10.21873/anticanres.15500
doi:

Substances chimiques

Antibodies, Anti-Idiotypic 0
CD8 Antigens 0
Immune Checkpoint Inhibitors 0
PDCD1 protein, human 0
Programmed Cell Death 1 Receptor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

419-427

Informations de copyright

Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Haruo Miyata (H)

Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.

Yasuto Akiyama (Y)

Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan y.akiyama@scchr.jp.

Akira Iizuka (A)

Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.

Ryota Kondou (R)

Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.

Chie Maeda (C)

Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.

Akari Kanematsu (A)

Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.

Kyoko Watanabe (K)

Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.

Tadashi Ashizawa (T)

Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.

Takeshi Nagashima (T)

Cancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
SRL, Tokyo, Japan.

Kenichi Urakami (K)

Cancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.

Keiichi Ohshima (K)

Medical Genetics Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.

Takuya Kawata (T)

Division of Pathology, Shizuoka Cancer Center Hospital, Shizuoka, Japan.

Koji Muramatsu (K)

Division of Pathology, Shizuoka Cancer Center Hospital, Shizuoka, Japan.

Akio Shiomi (A)

Division of Colon and Rectal Surgery, Shizuoka Cancer Center Hospital, Shizuoka, Japan.

Masanori Terashima (M)

Division of Gastric Surgery, Shizuoka Cancer Center Hospital, Shizuoka, Japan.

Takashi Sugino (T)

Division of Pathology, Shizuoka Cancer Center Hospital, Shizuoka, Japan.

Akifumi Notsu (A)

Clinical Trial Coordination Office, Shizuoka Cancer Center Hospital, Shizuoka, Japan.

Keita Mori (K)

Clinical Trial Coordination Office, Shizuoka Cancer Center Hospital, Shizuoka, Japan.

Ken Yamaguchi (K)

Shizuoka Cancer Center, Shizuoka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH